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Abstract 
Context: Urinary biomarkers are promising as simple alternatives to cystoscopy for 
the diagnosis of de novo and recurrent bladder cancer.  
Objective: To identify a highly sensitive and specific biomarker candidate set with 
potential clinical utility in bladder cancer. 
Materials and methods: Urinary biomarkers concentrations were determined by 
ELISA. The performance of individual markers and marker combinations was 
assessed using ROC analysis.  
Results: A 5-biomarker panel (IL8, MMP9, VEGFA, PTGS2 and EN2) was defined 
from the candidate set.  
Discussion and conclusion: This panel showed a better overall performance than the 
best individual marker. Further validation studies are needed to evaluate its clinical 
utility in bladder cancer. 
 
 
 
 
 
 
  
Introduction 
Bladder cancer is the ninth most common cancer worldwide based on incidence 
(Ferlay et al., 2013). About 75-85 % of patients have non-muscle invasive bladder 
cancer (NMIBC) at first diagnosis (Babjuk et al., 2011). Although these tumors are 
associated with good prognosis, there is a 50 to 70% recurrence rate with a 
probability of progression to muscle invasiveness in 10 to 30%  (Clark et al., 2013; 
Hall et al., 2007; Sylvester et al., 2006). Consequently, lifelong surveillance is 
essential for early recurrence detection. 
Both diagnosis and surveillance of bladder cancer rely on cystoscopy and urine 
cytology methods (Babjuk et al., 2011). Cystoscopy is highly sensitive and while 
considered the ‘gold standard’, it has a significant false-negative rate due to 
operator-dependent variability or to the difficulty of detecting in situ lesions.  
Furthermore, it is a costly and invasive procedure which is unpleasant for patients, 
and carries an additional 10% risk of developing urinary tract infection (Budman et 
al., 2008; Shariat et al., 2008).  Urine cytology has a higher specificity, ranging from 
85 to 100%, but lacks sensitivity (13-75%), especially when it comes to the detection 
of low-grade tumors (van Rhijn et al., 2005).  
In this context and taking into account the limitations mentioned above, alternative 
non-invasive methods such as measurements of urinary markers appear more and 
more appropriate for the diagnosis and surveillance of bladder cancer.  
Urine-based biomarker discovery was enabled by the advent of high-throughput 
Omics technologies (Ramachandran et al., 2008; Urquidi et al., 2012). Many markers 
were identified for their potential utility in the detection and monitoring of bladder 
cancer such as NMP22, BTA, BLCA-4, CYFRA21-1, survivin, hyaluronic acid and 
hyaluronidase (Konety et al., 2000; Shariat et al., 2009, 2008; Van Tilborg et al., 
2009; Vrooman and Witjes, 2008). Urinary tests have been developed for some of 
them, including bladder tumor antigen (BTA) and nuclear matrix protein 22 (NMP22). 
Two BTA assays, BTA TRAK® and BTA stat® (Polymedco, USA) are approved by 
the FDA for monitoring of bladder cancer in conjunction with cystoscopy. The Alere 
NMP22® BladderChek® Test is FDA-approved for the diagnosis and monitoring of 
bladder cancer patients in conjunction with standard diagnostic procedures. 
Compared to urine cytology which has a median sensitivity of 35% and a median 
specificity of 94% (van Rhijn et al., 2005), these tests exhibit better sensitivity (24-
89% for BTA TRAK®, 57-79% for BTA stat® and 49.5-65% for NMP22) but lower 
specificity (52-93% for BTA TRAK®, 48-95% for BTA stat® and 40-87.3 % for 
NMP22) as they are influenced by benign urological conditions such as 
inflammation, urinary lithiasis or benign prostatic hyperplasia. (Vrooman and Witjes, 
2008).  
The ideal marker should have both high sensitivity and high specificity in order to 
replace or decrease the need for cystoscopy and guide the surveillance scheme. 
Lack of specificity as outlined above for BTA and NMP2 is common to all described 
urinary markers and the best approach to address this specificity problem of 
individual markers may be to combine several biomarkers in a panel detectable by a 
multiplex assay. 
 
In this report, the selection and pre-validation of bladder cancer biomarkers are 
described. Basis for selection of appropriate marker candidates was the construction 
of a molecular disease model for bladder cancer and the identification of bladder 
cancer disease relevant molecular processes taking into account background Omics 
and literature datasets. Marker selection focused on covering relevant molecular 
disease processes by selecting at least one marker for every detected biological 
process also considering available biomarker evidence from scientific literature.  
 
The biomarker candidate set was then evaluated in a technical feasibility study using 
urinary samples from both bladder cancer patients and healthy donors. The 
evaluation led to a selection of markers with potential clinical utility to be included in 
a multiplex assay.  
 
Materials and methods 
Specimen and data collection 
Urine samples were collected from patients with cystoscopic and histological 
evidence of bladder cancer and controls. The latter were age and sex matched 
individuals who had no ongoing or previous cancer,  were non-smokers,  were not on 
medication, no urinary symptoms or history of prior bladder disorders apart from 
occasional urinary tract infection. First pass urines were collected according to a 
standard operating procedure and were spun at 150g for 10 minutes. The 
supernatant was aliquoted into 1 ml samples and frozen and stored at -80°C. All 
individuals gave informed consent for sample donation and the collection was 
approved by local ethical committee (ref 13/LO/0739). For patients with cancer, the 
histological report was prepared by an uro-pathologist additionally containing 
information to tumor stage and grade for each patient. 
 
 
Bladder cancer model and selection of biomarker candidate set 
We first created a set of bladder cancer disease genes consisting (i) of molecular 
features derived via an automatic literature mining approach for bladder cancer 
associated genes and (ii) of molecules reported as being deregulated in non-muscle-
invasive bladder cancer (NMIBC) Omics studies. The literature derived set was 
generated via gene2pubmed mappings for publications retrieved with the PubMed 
query ("Urinary Bladder Neoplasms/diagnosis" [majr]) OR ("Urinary Bladder 
Neoplasms/genetics" [majr]) OR ("Urinary Bladder Neoplasms/pathology" [majr]) OR 
("Urinary Bladder Neoplasms/physiopathology" [majr]) OR ("Urinary Bladder 
Neoplasms/urine" [majr]) in March 2013. 
Deregulated molecular features were furthermore extracted from high-throughput 
Omics studies, namely genome-wide association studies (GWAS), transcriptomics 
mRNA and miRNA studies, proteomics, as well as metabolomics studies, in the 
focus of disease diagnosis of bladder cancer fulfilling the following requirements: 
(i) A study on human samples 
(ii) Sample material had to be from untreated patients 
(iii) Focus of the study had to be disease diagnosis 
(iv) The analysis approach of the study had to be unbiased 
(v) Tumor category: superficial bladder cancer (NMIBC), early stage (pTis, 
pTa, pT1); early/intermediate grade (1 or 2) 
(vi) Tumor type: transitional cell carcinoma 
(vii) Origin: mucosa 
(viii) For proteomics and metabolomics, studies conducted in urine were 
included 
 
Studies passing this manual curation step were forwarded to molecular feature 
extraction thus complementing the list of features available after the automatic 
literature mining approach. Metabolites were mapped to their enzymes via 
information in the Human Metabolome Database [http://www.hmdb.ca/] and miRNAs 
were mapped to their target genes via information in miRTarBase 
[http://mirtarbase.mbc.nctu.edu.tw/]. Data sources used for molecular features as 
well as mapping for building the molecular model are listed in Appendix B. 
 
The molecular model was constructed for NMIBC using the bladder cancer 
molecular features set following the procedure as outlined in Heinzel et al. (Heinzel 
et al., 2014) with the omicsNET protein dependency network as underlying biological 
network (Fechete et al., 2013). 
 
Each process unit of the resulting network was evaluated regarding evidence of 
association to bladder cancer by comparing the distribution of paper counts for each 
process unit member to a reference distribution of all human genes having at least 
one disease association as derived from literature mining. 
 
All process units were further evaluated regarding the capability of individual process 
unit members to separate healthy controls [n=48] from diseased samples [n=28] in 
the publicly available  transcriptomics dataset from Sanchez-Carbayo (Sanchez-
Carbayo et al., 2006). Distribution of single process unit member AUC values were 
tested against the reference set of all mRNA features on the array of the 
transcriptomics study in order to identify those process units showing good 
performance in separating cases from controls. 
 Association to bladder cancer was evaluated for each member of the resulting 
molecular model based on gene2pubmed mappings of scientific articles retrieved 
with the following PubMed query: Urinary Bladder Neoplasms[majr]. 
 
In addition a list of marker candidates was generated based on a literature search 
using the following query followed by the extraction of genes via gene2pubmed: 
"Urinary Bladder Neoplasms/urine"[majr] AND “Biological Markers”[mh]. 
 
A third number was derived for each molecule in the molecular model on the number 
of publications reporting the respective molecule as biomarker for bladder cancer in 
urine using the following PubMed query: "Urinary Bladder Neoplasms/urine"[majr] 
AND “Biological Markers”[mh]. 
 
Enzyme-linked immunosorbent assays (ELISA) for urinary biomarkers 
Commercially available ELISA kits were used to measure urinary levels of the 
different markers. Appendix C gives the 20 kits sources and references.  
The assays were conducted according to the manufacturer’s instructions using an 
EVO75 robotic platform (Tecan, France).  
Engrailed-2 (EN2) protein levels were also determined by ELISA (Morgan et al., 
2013). A monoclonal mouse anti-EN2 antibody, APS1, was generated (Antibody 
Production Services Ltd., UK) using the synthetically produced EN2 C-terminal 100 
amino acids (Biosynthesis Inc., USA). APS1 was used to detect EN2 coated on a 96-
well plate (Immuno Clear Standard Modules, Cat # 434797 Thermo Scientific, USA). 
APS1 was then detected using an anti-mouse IgG (γ chain specific) - peroxidase 
conjugate (Calbiochem, Germany).  
For each assay, a calibration curve in assay diluent and a calibration curve in normal 
human urine (UTAK Laboratories, USA) were prepared. EN2 calibration curves were 
generated from dilution series of one of the bladder cancer urinary samples. For all 
the other markers, calibration curves were prepared using protein standards 
provided in the ELISA kits. Curve fitting was accomplished using four-parameter 
logistic regression. 
Due to the high degree of variability of voided urine (Thomas et al., 2010; Urquidi et 
al., 2012), the concentrations of all markers were normalized to urinary creatinine 
(measured with ADVIA 1800 Chemistry System, Siemens) and expressed as a ratio 
to urinary creatinine values. 
 
Data analysis 
A receiver operating characteristic (ROC) analysis was performed to assess the 
performance of individual markers using the PanelomiX software 
(http://www.panelomix.net/) (Robin et al., 2013). PanelomiX also allowed ROC 
analysis of panels by testing various combinations of markers based on the iterative 
combination of biomarkers and thresholds (ICBT) method. 
 
Results 
 
Bladder cancer model and selection of biomarker candidate set 
The bladder cancer disease gene set held 1384 unique protein coding genes with 
587 genes extracted from scientific literature complemented by 897 molecules 
extracted from the Omics datasets on NMIBC. The constructed molecular model of 
NMIBC held 520 proteins in 30 process units ranging in size from 3 to 162. Five 
process units were significantly enriched in proteins associated with bladder cancer 
as compared to the reference set of genes being associated with at least one 
disease term via gene2pubmed which were considered as relevant for biomarker 
selection. AUC values in separating cases from controls in the transcriptomics 
dataset from Sanchez-Carbayo were significantly higher for members of four 
additional process units which were also considered for biomarker selection. 
 
A schematic representation of the molecular model is given in the Figure 1. Based 
on the number of associations to bladder cancer the most promising molecules were 
selected for relevant molecular process units. This marker set was complemented by 
four molecules with high evidence in the scientific literature but not being part of the 
molecular model resulting in a set of 20 marker candidates as given in Table 1. 
 
Following the identification of this biomarker candidate set, the evaluation of markers 
was performed in a two-step selection process: a first evaluation for measurability 
and detectability in urine samples followed by a second evaluation for confirmation of 
the markers’ selectivity for bladder cancer. 
 
 
First evaluation of candidate biomarkers: measurability and detectability in 
urine 
The biomarker candidate set consisting of 20 markers was evaluated in urine 
samples of bladder cancer patients and healthy donors.  
Measurability in urine was first ascertained as the performance of many ELISAs may 
be significantly affected by the urinary environment due to changes in pH or 
urea/creatinine levels. Columns 2 and 3 of Table 2 present the measurability of each 
marker (standard solution from kit) in kit manufacturer buffer and standardized urine, 
respectively. Four out of the 20 ELISA tests weren’t able to detect their specific 
target in urine (CD44, AP1M2, CDH1 and ERBB2). On the contrary, MYC was 
detected in urine but not in manufacturer buffer. 
Detectability in urine samples from bladder cancer patients was then evaluated using 
the kits able to detect standard solution in urine. Out of the 16 remaining tests, 10 
were able to detect markers in patient urine (MMP9, EN2, VEGFA, EGFR, IL8, DCN, 
MYC, UPK3A, PTGS2 and FGFR3). 
 
Second evaluation of candidate biomarkers: markers’ selectivity for bladder 
cancer 
The 10 selected markers underwent a second evaluation step using a set of 32 
samples (16 bladder cancer patients and 16 healthy donors). Clinical and 
pathological characteristics of the 32 subjects are presented in Appendix A. 
Figure 2 presents the marker concentrations in samples determined with commercial 
ELISA kits using the four-parameter logistic regression and normalized to urinary 
creatinine. For each marker, the cut-off value was calculated as the mean 
concentration of all healthy donor samples + 3SD (99.7% of the healthy population is 
below this value). Eight of the ten markers showed at least one positive patient 
sample concentration, i.e., above the cut-off value. Three markers (VEGFA, DCN 
and UPK3A) showed a cut-off value of zero as no protein was detected in the 
healthy donor samples. Patient samples showing detectable marker signals were 
considered positive. Four other markers (MMP9, IL8, MYC and EN2) showed one 
healthy donor marker concentration above the cut-off value, thus generating false 
positives. Finally, PTGS2 was the only marker for which none of the samples from 
both populations had a concentration above the cut-off value. 
Marker performance was evaluated using ROC analysis with performance values of 
the individual markers given in Table 3. MMP9 was the most accurate marker with 
an AUC of 0.742 (95% CI: 0.560-0.923). Using the optimal threshold (determined by 
PanelomiX ICBT method), MMP9 revealed a sensitivity of 86.7% (95% CI: 66.7-
100.0%) and specificity of 68.8% (95% CI: 43.8-87.5%). The markers VEGFA and 
DCN were only detected in patient samples and thus provided high specificity values 
of 100% but low sensitivity values of 20.0% (95% CI: 0.0-40.0%) and 13.3% (95% 
CI: 0.0-33.3%) for VEGFA and DCN respectively. UPK3A could not be included in 
the ROC analysis as the protein was detected only in one sample.  
 
ROC analysis was also performed for multiple markers and PanelomiX threshold-
based algorithm was used to test all combinations of biomarkers (excluding UPK3A). 
The best performing marker panel achieved an AUC of 0.871 (95% CI: 0.723-1.0) 
and of 0.81 (95% CI: 0.640-0.981) after cross-validation including the following six 
markers: MMP9, VEGFA, IL8, PTGS2, FBLN3, and EN2 (Table 4). 
 
Excluding FBLN3 from the model resulted in only marginally reduced overall 
performance but drastically increased specificity at the expense of reduced 
sensitivity. As specificity is the parameter of major interest in clinical practice the 
following marker panel was defined as the one to be multiplexed on a chip (Table 5 
and Figure 3). 
 Discussion 
Patient-specific biomarker profiles could be of predictive and prognostic utility and 
could contribute to evidence-based bladder cancer patient management. As no 
single biomarker can achieve the desired accuracy, a multi-marker test would 
logically be more likely to be successful. In this regard, we have identified a urinary 
biomarker candidate set and evaluated it in bladder cancer urine samples, leading to 
the selection of a panel of five markers: IL8, MMP9, VEGFA, PTGS2 and EN2. 
This panel showed a better overall performance than the best individual marker 
(MMP9), achieving an AUC of 0.865 (0.727-1.0) whereas MMP9 reached an AUC of 
0.742 (95% CI: 0.560-0.923). Even though the panel sensitivity is slightly reduced 
compared to MMP9 (80.0% and 86.7, respectively), its specificity, the most relevant 
parameter in this context, is considerably increased (93.8% vs. 68.8%). 
It is also important to note that due to a relatively small sample size (32 patients), 
confidence intervals are considerably large. 
 
Non-muscle-invasive bladder tumors have a tendency to recur with a risk of 
progression to muscle-invasive disease, highlighting the importance of monitoring 
patients to allow for early recurrence or progression detection (21). We analyzed the 
potential of our five-marker panel for predicting invasiveness. The role of the various 
markers with regards to invasiveness was thus evaluated based on the bladder 
cancer model and on a literature search about the mechanistic link to invasiveness. 
Each marker measured in the study was searched in the scientific literature in 
combination with the search term invasiveness or invasive. Resulting publications 
were manually screened and paragraphs discussing the respective marker in the 
context of invasiveness were extracted and collected. In addition, links to other 
markers from the lists in the publications on invasiveness were extracted and 
consolidated. 
A schematic pathway diagram was constructed based on the information extracted 
from publications (Figure 4). This diagram emphasizes the roles of MMP9, VEGFA, 
EGFR, IL8 and PTGS2 in bladder cancer invasiveness. Indeed, it was found that 
matrix metalloproteinases, including MMP9, promote tumor invasion and alter 
microenvironment. They may be thus associated with the development of invasive 
bladder cancer (Kader et al., 2007). Moreover, the mechanism of MMP9 activation 
involves EGF/EGFR signaling activities (Pei et al., 2014) as well as IL8 expression 
(Inoue et al., 2000). Angiogenic activity is also enhanced by the expression of VEGF 
and its receptors VEGFR1/VEGFR2, promoting tumor proliferation and invasion 
(Kopparapu et al., 2013; Nakanishi et al., 2009). Additionally, PTGS2 has a role in 
bladder cancer development and invasion and is associated with angiogenesis as 
well (Gee et al., 2008; Margulis et al., 2007). 
Four of the markers included in the final panel are thus linked to invasiveness: IL8, 
MMP9, VEGFA and PTGS2. The remaining marker, EN2, has no reported link to 
invasiveness so far in the literature. Nevertheless, its inclusion in the final panel is 
justified by its contribution to overall performance of the marker panel and previous 
reports on this marker as bladder cancer marker (Morgan et al., 2013). EGFR on the 
other hand was not included in the panel as it did not increase overall performance 
although mechanistically linked to invasiveness.  
 
 
Conclusions 
Marker candidates were selected on the basis of a molecular disease model for 
bladder cancer. A 5-biomarker panel (IL8, MMP9, VEGFA, PTGS2 and EN2) was 
then defined from the candidate set by evaluating the measurability and detectability 
as well as the selectivity for bladder cancer of the candidate markers in urine 
samples. 
Although this preliminary study only investigated the diagnostic aspect of bladder 
cancer (in terms of detectability), it was followed by an analysis of the selected panel 
showing its potential for the prediction of invasiveness.  
A scoring system, developed by the European Organization for Research and 
Treatment of Cancer (EORTC), is already available to predict the risks of both 
recurrence and progression in individual superficial bladder cancer patients 
(Sylvester et al., 2006). However, it is based only on clinical and pathological factors 
such as the number of tumors, tumor size and T category.  
Biomarker profiles, such as defined by our selected panel, could have a great impact 
on clinical management of bladder cancer patients. Indeed, the surveillance scheme 
as well as the treatment strategy could be modified according to the risk of 
invasiveness and/or recurrence assessed at the time of diagnosis and based on the 
urinary biomarker levels of the defined panel.  
Finally, it is important to note that the present study includes a small number of 
samples (32 patients). Thus, there is a need for further clinical validation with a 
greater sample size. A multiplex assay shall then be now developed to detect this 
panel in high-throughput to consolidate this first validation study. 
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Appendices 
Appendix A: Patient characteristics of the study cohort 
 
 
Healthy donors (%) 
N = 16 
Bladder cancer patients 
(%) 
N = 16 
Age, y   
Mean [median] 71.1 [71] 73.3 [73] 
Range 59 - 82 65 -83 
Sex   
Male 16 (100) 14 (87.5) 
Female 0 (0) 2 (12.5) 
Clinical stage*   
Ta N/A 10 (66.7) 
T1 N/A 4 (26.7) 
T2 N/A 1 (6.6) 
Tumor grade*   
G1 N/A 1 (6.7) 
G2 N/A 11 (73.3) 
G3 N/A 3 (20) 
 
*One subject with metastatic bladder cancer, not included in clinical stage and tumor 
grade 
N/A: not applicable 
 
 
 
 
Appendix B: Data sources of the molecular model 
 
Author-
Year 
PubMed 
ID Omics type Study title 
Garcia-
Closas-
2011 
21824976 genomics 
A genome-wide association study of bladder 
cancer identifies a new susceptibility locus within 
SLC14A1, a urea transporter gene on 
chromosome 18q12.3 
Rafnar-
2011 
21750109 genomics 
European genome-wide association study 
identifies SLC14A1 as a new urinary bladder 
cancer susceptibility gene 
Rothman
-2010 
20972438 genomics 
A multi-stage genome-wide association study of 
bladder cancer identifies multiple susceptibility loci 
Wu-2009 19648920 genomics 
Genetic variation in the prostate stem cell antigen 
gene PSCA confers susceptibility to urinary 
bladder cancer 
Golka-
2011 
21380501 genomics 
Genetic variants in urinary bladder cancer: 
collective power of the "wimp SNPs" 
Mengual
-2009 
19539325 
mRNA 
transcriptomics 
DNA microarray expression profiling of bladder 
cancer allows identification of noninvasive 
diagnostic markers 
Sanchez
-
Carbayo-
2006 
16432078 
mRNA 
transcriptomics 
Defining molecular profiles of poor outcome in 
patients with invasive bladder cancer using 
oligonucleotide microarrays 
Dyrskjot-
2004 
15173019 
mRNA 
transcriptomics 
Gene expression in the urinary bladder: a 
common carcinoma in situ gene expression 
signature exists disregarding histopathological 
classification 
Catto-
2009 
19843843 
miRNA 
transcriptomics 
Distinct microRNA alterations characterize high- 
and low-grade bladder cancer 
Linden-
2012 
22065568 proteomics 
Proteomic analysis of urinary biomarker 
candidates for nonmuscle invasive bladder cancer 
Niu-2009 18818109 proteomics 
Differences in shotgun protein expression profile 
between superficial bladder transitional cell 
carcinoma and normal urothelium 
Jobu-
2012 
22466574 metabolomics 
Metabolomics study on the biochemical profiles of 
odor elements in urine of human with bladder 
cancer 
Putluri-
2011 
21990318 metabolomics 
Metabolomic profiling reveals potential markers 
and bioprocesses altered in bladder cancer 
progression 
Pasikanti
-2010 
20337499 metabolomics 
Noninvasive urinary metabonomic diagnosis of 
human bladder cancer. 
 
  
Appendix C: ELISA kits references 
Marker Full name Company Cat No 
MMP9 matrix metalloproteinase 9 Abcam ab100610 
EN2 engrailed-2 Cusabio CSB-EL007660HU 
VEGFA 
vascular endothelial 
growth factor 
Cusabio CSB-E11718h 
VIM vimentin Abnova KA3127 
CD44 
CD44 molecule (Indian 
blood group) 
Abnova KA0119 
IL8 interleukin 8 Abcam ab46032 
EGFR 
epidermal growth factor 
receptor 
Sigma-
Aldrich 
RAB0160-1KT 
RARB retinoic acid receptor, beta 
USCN Life 
Science 
SED951Hu 
PTGS2 
prostaglandin-
endoperoxide synthase 2 
Uscn Life 
Science 
SEA699Hu 
DCN decorin Abcam ab99998 
MYC 
V-Myc myelocytomatosis 
viral oncogene homolog 
BlueGene 
Biotech 
E01C0774 
AP1M2 
adaptor-related protein 
complex 1, mu 2 subunit 
Cusabio CSB-EL001865HU 
FGFR3 
fibroblast growth factor 
receptor 3 
Cusabio CSB-EL008646HU 
TMOD1 tropomodulin 1 Cusabio CSB-EL023909HU 
UPK3A uroplakin 3A Cusabio CSB-EL025657HU 
BIRC5 
baculoviral IAP repeat 
containing 5 (survivin) 
Abnova KA0441 
CDH1 cadherin-1 Abnova KA0433 
FBLN3  fibulin 3 
USCN Life 
Science 
SEF422Hu 
p53 cellular tumor antigen p53 
Sigma-
Aldrich 
RAB0500-1KT 
ERBB2 
receptor tyrosine-protein 
kinase erbB-2 
Sigma-
Aldrich 
RAB0173-1KT 
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Table 1. Marker list 
Process unit Symbol AUC # BC 
papers 
# BC marker 
papers 
# BC 
marker 
papers 
(urine) 
4 PTGS2 0,908 8 4 1 
4 RARB 0,958 3 2 1 
5 TP53 0,866 70 12 0 
5 IL8 0,692 6 2 0 
5 VEGFA 0,876 10 4 0 
3 MYC 0,763 10 2 0 
1 EGFR* 0,684 10 5 1 
1 ERBB2* 0,981 16 15 0 
1 FGFR3* 0,990 46 7 0 
7 CD44 0,929 7 6 1 
7 MMP9 0,539 5 2 1 
23 EFEMP1 0.993 0 0 0 
12 VIM 0.896 2 2 0 
12 TMOD1 1.000 0 0 0 
25 DCN 0.999 0 0 0 
29 AP1M2 0.997 0 0 0 
- BIRC5 0,918 11 7 2 
- CDH1 0,984 19 9 0 
- UPK3A* 0,842 3 1 0 
- EN2 0.531 1 1 1 
Process unit: process unit number of the molecular NMIBC model 
Symbol: Official Gene Symbol 
AUC: Single AUC value in the transcriptomics dataset by Sanchez-Carbayo (red if 
upregulated in diseased samples; green if downregulated in diseased samples) 
# BC papers: number of bladder cancer papers addressing the respective gene 
# BC marker papers: number of BC papers addressing the respective gene as marker 
# BC marker papers: number of BC papers addressing the respective gene as marker 
in urine 
* indicates if the protein is a receptor 
  
Table 2. Marker evaluation in urine samples 
Marker Calibration 
curve in 
assay 
diluent 
Calibration 
curve in urine 
LOD (urine)† Marker detection in 
patient samples 
MMP9 + + 0.222 ng/mL + 
EN2* + + 1.25 ng/mL + 
VEGFA + + 0.0625 ng/mL + 
VIM + + 28.125 ng/mL - 
CD44 + - N/A - 
EGFR + + 0.1 ng/mL + 
IL8 + + 0.1 ng/mL + 
RARB + + 0.625 ng/mL - 
PTGS2 + + 2.5 ng/mL + 
DCN + + 25.9 pg/mL + 
MYC - + 1 ng/mL + 
AP1M2 + - NA - 
FGFR3 + + >250 pg/mL - 
TMOD1 + + 1.25 ng/mL - 
UPK3A + + 100 pg/mL + 
BIRC5 + + 200 pg/mL - 
CDH1 + - N/A - 
FBLN3 + + >3.12 ng/mL + 
p53 + + 2.5 ng/mL - 
ERBB2 + - N/A - 
+ : presence of calibration curve or marker detection in samples; - :absence of 
calibration curve or no marker detection in samples; N/A: not applicable; LOD: limit 
of detection 
*EN2 was detected using direct coating of the urine sample. 
†The limits of detection were determined visually on the calibration curves. 
  
Table 3. Individual biomarker performance sorted by AUC 
Marker % AUC (95% CI) % Sp (95% CI) % Se (95% CI) 
MMP9 74.2 (56.0-92.3) 68.8 (43.8-87.5) 86.7 (66.7-100.0) 
EN2 66.0 (47.8-84.3) 87.5 (68.8-100.0) 53.3 (26.7-80.0) 
IL8 65.4 (48.9-81.9) 81.2 (62.5-100.0) 46.7 (20.0-73.3) 
VEGFA 60.0 (49.5-70.5) 100.0 (100.0-100.0) 20.0 (0.0-40.0) 
PTGS2 57.7 (38.7-76.7) 68.8 (43.8-87.5) 53.3 (26.7-80.0) 
DCN 56.7 (47.8-65.6) 100.0 (100.0-100.0) 13.3 (0.0-33.3) 
EGFR 54.0 (38.5-69.4) 87.5 (68.8-100.0) 26.7 (6.7-46.7) 
FBLN3 47.5 (26.1-68.9) 56.2 (31.2-81.2) 60.0 (33.3-86.7) 
MYC 47.1 (36.5-57.7) 93.8 (81.2-100.0) 6.7 (0.0-20.0) 
AUC: area under the curve; CI: confidence interval; Sp: specificity; Se: sensitivity 
No performance characteristics could be obtained for UPK3A since the protein was 
detected in one sample only and thus only one nonzero value was available for the 
analysis. 
 
  
 Table 4. Best panel performance 
Panel  % AUC (95% CI) % Sp (95% CI) % Se (95% CI) 
MMP9 
VEGFA 
IL8 
PTGS2 
FBLN3 
EN2 
Training 
 
81.2 (62.5-100.0) 93.3 (80.0-100.0) 87.1 (72.3-100.0) 
    
Cross-
validation 
81.0 (64.0-98.1) 68.8 (43.8-93.8) 93.3 (80.0-100.0) 
AUC: area under the curve; CI: confidence interval; Sp: specificity; Se: sensitivity 
Cross-validation procedure for panel verification: 10-fold cross-validation repeated 5 
times  
  
Table 5. Performance of final biomarker panel 
Panel  % AUC (95% CI) % Sp (95% CI) % Se (95% CI) 
MMP9 
VEGFA 
IL8 
PTGS2 
EN2 
Training 86.5 (72.7-100.0) 
  
93.8 (81.2-100.0) 80.0 (60.0-100.0) 
    
Cross-
validation 
81.9 (66.3-97.5) 87.5 (68.8-100.0) 73.3 (53.3-93.3) 
AUC: area under the curve; CI: confidence interval; Sp: specificity; Se: sensitivity  
Cross-validation procedure for panel verification: 10-fold cross-validation repeated 5 
times 
  
Figure captions 
 
Figure 1. Schematic representation of the constructed molecular model of bladder 
cancer. Each node represents a molecular process unit whereas the size 
corresponds to number of proteins within this unit. 
 
Figure 2. Marker concentrations in healthy donor and bladder cancer patient 
samples, normalized to urinary creatinine. 
Concentrations were determined with commercial ELISA kits with the exception of 
EN2. Cut-off values were calculated as the mean concentration of all healthy donor 
samples + 3SD. 
a.u.: arbitrary unit 
 
Figure 3. Receiver operating characteristics (ROC) curves of the final panel (black) 
and of MMP9 (grey) on training set (left) and test set (right) 
 
Figure 4. Schematic pathway for bladder cancer invasiveness development (Kader 
et al., 2007; Pei et al., 2014; Donmez et al., 2009; Bettum et al., 2014).  
BC: bladder cancer 
 
